According to The Insight Partners' research, the Asia Pacific Anti-Obesity Drugs Market was valued at US$ 1,317.2 Million in 2024 and is expected to reach US$ 15,476.6 Million by 2031, registering a CAGR of 45.7% from 2025 to 2031.
Increased awareness and demand for weight management solutions and expansion in emerging economies are among the critical factors attributed to driving the Asia Pacific anti-obesity drugs market growth.
The growing awareness of obesity and its health risks has greatly increased the demand for effective weight management solutions. Concerns about diseases related to lifestyle have led many to look for medical and pharmaceutical help. This awareness is leading to greater acceptance and use of anti-obesity drugs in treatment plans. Furthermore, media reports and public health campaigns are informing people about options for managing obesity. As a result, the market for anti-obesity drugs is seeing rapid growth around the world. Governments and pharmaceutical companies are increasing their efforts to educate the public about the dangers of obesity, particularly its links to diabetes, cardiovascular disease, and other chronic conditions.
In December 2022, Novo Nordisk launched the "Break the Partnership" campaign to educate individuals with diabetes, their caregivers, and healthcare professionals about the impact of weight on type 2 diabetes management. Officially launched by former cricketer Kapil Dev, the campaign encouraged discussions with clinicians about new treatment options that addressed blood glucose levels and weight. Over the following six months, the Novo Nordisk team engaged healthcare professionals through awareness events and scientific meetings in various cities. The growing awareness of obesity as a serious health condition has significantly increased the demand for effective weight management solutions, particularly drug-based therapies. Public health campaigns, medical endorsements, and pharmaceutical innovations have collectively contributed to greater acceptance and usage of anti-obesity medications. This shift reflects a broader change in consumer behavior and healthcare approaches towards managing obesity with scientific and pharmaceutical support. Consequently, the anti-obesity drugs market is poised for sustained growth, driven by ongoing advancements and rising patient demand.
On the contrary, side effects and safety concerns hamper the growth of the Asia Pacific anti-obesity drugs market.
Asia Pacific Anti-Obesity Drugs Market Segmentation Analysis:
- By Type, the Asia Pacific Anti-Obesity Drugs Market is segmented into Prescription Drugs and OTC Drugs. The Prescription Drugs segment is projected to expand at 45.9% CAGR during 2025 - 2031.
- By Mechanism of Action, the Asia Pacific Anti-Obesity Drugs Market is segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others. The Centrally Acting Drugs segment is projected to expand at 46.1% CAGR during 2025 - 2031.
- By Drug Class, the Asia Pacific Anti-Obesity Drugs Market is segmented into GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and Others. The GLP-1 Agonist segment is projected to expand at 50.5% CAGR during 2025 - 2031
- By GLP-1 agonist, the Asia Pacific Anti-Obesity Drugs Market is segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound). The Semaglutide segment is projected to expand at 52.5% CAGR during 2025 - 2031.
- By Application, the Asia Pacific Anti-Obesity Drugs Market is segmented into Appetite Suppression, Inhibition of Fat Absorption or Digestive Enzymes, Metabolic Enhancement, and Combination. The Appetite Suppression segment is projected to expand at 46.8% CAGR during 2025 - 2031.
- By Route of Administration, the Asia Pacific Anti-Obesity Drugs Market is segmented into Oral and Parenteral. The Oral segment is projected to expand at 46.7% CAGR during 2025 - 2031.
- By Distribution Channel, the Asia Pacific Anti-Obesity Drugs Market is segmented into Hospital Pharmacies, Online Channel, and Retail Pharmacies. The Hospital Pharmacies segment is projected to expand at 46.5% CAGR during 2025 - 2031.
By country, the Asia Pacific Anti-Obesity Drugs Market is categorized into China, Japan, India, Australia, South Korea, Rest of APAC. China is projected to expand at 49.6% CAGR during 2025 - 2031.
Key players operating in the Anti-Obesity Drugs Market are GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC., AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc, among others.
- In 2025, Rhythm Pharmaceuticals Inc. received orphan drug designation from Japan's Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com